Study Finds Hyperprogression After Immunotherapy in NSCLC Subset – OncLive
OncLive |
Study Finds Hyperprogression After Immunotherapy in NSCLC Subset
OncLive Although anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer (NSCLC) and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor … |
